Cefmatilen (INN, codenamed S-1090) is an orally-active cephalosporin antibiotic. It was developed in Japan and first described in 1992.[1]
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C15H14N8O5S4 |
Molar mass | 514.57 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
In vitro, cefmatilen is highly active against a variety of Gram-positive and Gram-negative bacteria, including Streptococcus pyogenes and Neisseria gonorrhoeae.[1]
References
edit- ^ a b Tsuji M, Ishii Y, Ohno A, Miyazaki S, Yamaguchi K (November 1995). "In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporin". Antimicrob Agents Chemother. 39 (11): 2544–51. doi:10.1128/aac.39.11.2544. PMC 162981. PMID 8585742.
Further reading
edit- Cazzola M (February 2000). "Novel oral cephalosporins". Expert Opin Investig Drugs. 9 (2): 237–46. doi:10.1517/13543784.9.2.237. PMID 11060674. S2CID 45932120.